A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy

作者：Zhiyong Shi, Miaomiao Liu, Xiaowen Zhang, Jingyang Wang, Junwei Zhang, Zeyan Peng, Meng Li, Ruijing Wang, Lihong Guo, Qiang Zhang, Jing Li, Liang Yang, Jie Liu, Yang Xu, Jie Yan, Jianlin Cui, Shan Ren, Yang Gao, Yanming Wang, Zhi Qi · 发表于：Theranostics · 年份：2024 · DOI：10.7150/thno.92119 · 被引用次数：11 · 研究领域：Histone Deacetylase Inhibitors Research、Fullerene Chemistry and Applications、Peptidase Inhibition and Analysis

results showed that SeSA-DCA is a highly effective anti-tumor compound for PCa. It can effectively induce cell cycle arrest and growth suppression and inhibit the migration and metastasis of PCa cell lines compared with monotherapy. SeSA-DCA's ability to decrease the growth of xenografts is a little better than that of docetaxel without any apparent signs of toxicity. Our findings provide an important theoretical basis for clinical prostate cancer treatment.